Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

CDK9:在HCC治疗中的治疗学前景

卷 20, 期 5, 2020

页: [318 - 324] 页: 7

弟呕挨: 10.2174/1568009620666200212124357

价格: $65

摘要

CDK9是一个重要的细胞周期控制酶，在转录、延长和mRNA的成熟中必不可少。CDK9超量表达在多种疾病中都有报道，包括急性淋巴细胞白血病、慢性淋巴细胞白血病和恶性黑色素瘤。近期研究显示，CDK9抑制剂在肝癌细胞列中诱导细胞凋亡起主要影响。尽管体外和体内研究的结果显著有希望的，但目前还不允许CDK9相关治疗方法用于HCC病例。此外，由于它们的高特异性，抑制剂对未改变的肝细胞没有影响，也没有显示毒性作用。考虑到CDK9抑制剂在小鼠中具有良好的耐受性和相对较少的严重副作用，CDK9抑制剂似乎是HCC生物标记引导的免疫治疗中有希望的靶点。研究已经证实CDK9在c- myc介导的肿瘤生长中起关键作用，CDK9抑制剂不仅可以抑制其进展，而且可以直接减少肝癌细胞结节的体积和大小。cdk9抑制剂似乎是治疗HCC的一个有希望的靶点。

关键词: CDK9

« Previous Next »
图形摘要

[1]
Franco, L.C.; Morales, F.; Boffo, S.; Giordano, A. CDK9: A key player in cancer and other diseases. J. Cell. Biochem., 2018, 119(2), 1273-1284.
[http://dx.doi.org/10.1002/jcb.26293] [PMID: 28722178]
[2]
Bacon, C.W.; D’Orso, I. CDK9: A signaling hub for transcriptional control. Transcription, 2018, 1-19.
[http://dx.doi.org/10.1080/21541264.2018.1523668] [PMID: 30227759]
[3]
Boffo, S.; Damato, A.; Alfano, L.; Giordano, A. CDK9 inhibitors in acute myeloid leukemia. J. Exp. Clin. Cancer Res. 37., 2018, 1-10.
[4]
Kretz, A.; Schaum, M.; Richter, J.; Kitzig, E.F.; Engler, C.C.; Leithäuser, F.; Henne-Bruns, D.; Knippschild, U.; Lemke, J. CDK9 is a prognostic marker and therapeutic target in pancreatic cancer. 2017, Tumour Biol., 39(2) 1010428317694304
[5]
Rahaman, M.H.; Kumarasiri, M.; Mekonnen, L.B.; Yu, M.; Diab, S.; Albrecht, H.; Milne, R.W.; Wang, S. Targeting CDK9: A promising therapeutic opportunity in prostate cancer. Endocr. Relat. Cancer, 2016, 23(12), T211-T226.
[http://dx.doi.org/10.1530/ERC-16-0299] [PMID: 27582311]
[6]
Itkonen, H.M.; Poulose, N.; Walker, S.; Mills, I.G. CDK9 inhibition induces a metabolic switch that renders prostate cancer cells dependent on fatty acid oxidation. Neoplasia, 2019, 21(7), 713-720.
[http://dx.doi.org/10.1016/j.neo.2019.05.001] [PMID: 31151054]
[7]
Brisard, D.; Eckerdt, F.; Marsh, L.A.; Blyth, G.T.; Jain, S.; Cristofanilli, M.; Horiuchi, D.; Platanias, L.C. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget, 2018, 9(99), 37305-37318.
[http://dx.doi.org/10.18632/oncotarget.26468] [PMID: 30647871]
[8]
Morales, F.; Giordano, A. Overview of CDK9 as a Target in Cancer Research. Cell Cycle, 2016, 15(4), 519-527.
[9]
Gudipaty, S.A.; Mcnamara, R.P.; Morton, E.L.; Orso, I.D. PPM1G Binds 7SK RNA and Hexim1 To Block P-TEFb Assembly into the 7SK snRNP and Sustain Transcription Elongation. Mol. Cell. Biol., 2015, 35(22), 3810-3828.
[10]
Nguyen, V.T.; Kiss, T.; Michels, A.A.; Bensaude, O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature, 2001, 414(6861), 322-325.
[http://dx.doi.org/10.1038/35104581] [PMID: 11713533]
[11]
Li, Q.; Price, J.P.; Byers, S.A.; Cheng, D.; Peng, J.; Price, D.H. Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing Cdk9 phosphorylated at threonine 186. J. Biol. Chem., 2005, 280(31), 28819-28826.
[12]
Villanueva, A.; Hernandez-Gea, V.; Llovet, J.M. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol., 2013, 10(1), 34-42.
[http://dx.doi.org/10.1038/nrgastro.2012.199] [PMID: 23147664]
[13]
Claudio, P.P.; Cui, J.; Ghafouri, M.; Mariano, C.; White, M.K.; Safak, M.; Sheffield, J.B.; Giordano, A.; Khalili, K.; Amini, S. Cdk9 phosphorylates p53 on serine 392 independently of CKII. J. Cell. Physiol., 2006, 612, 602-612.
[14]
Hellvard, A.; Zeitlmann, L.; Heiser, U.; Astrid, K.; Niestroj, A.; Demuth, H.; Koziel, J.; Delaleu, N.; Potempa, J.; Mydel, P. Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis. Nat. Publ. Gr., 2016.
[15]
Thomas, L.W.; Lam, C.; Edwards, S.W. Mcl-1; The molecular regulation of protein function. FEBS Lett., 2010, 584(14), 2981-2989.
[http://dx.doi.org/10.1016/j.febslet.2010.05.061] [PMID: 20540941]
[16]
Huang, C.; Lujambio, A.; Zuber, J.; Tschaharganeh, D.F.; Doran, M.G.; Evans, M.J.; Kitzing, T.; Zhu, N.; Stanchina, E. De.; Sawyers, C.L. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev., 2014, 1, 1800-1814.
[17]
Kulik, L.; El-serag, H.B. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 2018, 1-15.
[http://dx.doi.org/10.1053/j.gastro.2018.08.065] [PMID: 30367835]
[18]
Golabi, P.; Otgonsuren, M.; Sayiner, M.; Locklear, C.T.; Younossi, Z.M. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine, 96(9)
[http://dx.doi.org/10.1097/MD.0000000000005904]
[19]
Papendorf, F.; Kirchhoff, T.; Wohlberedt, T.; Kubicka, S.; Klempnauer, J.; Galanski, M. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br. J. Cancer, 92(10)2005, , 1862-1868.
[20]
Schwartz, J.M.; Carithers Jr, R.L.; Sirlin, C.B.; Kressel, H.Y.; Savarese, D.M. Clinical features and diagnosis of hepatocellular carcinoma. 2019.
[21]
Pardee, A.D.; Butterfield, L.H.; Pardee, A.D.; Butterfield, L.H. Immunotherapy of hepatocellular carcinoma immunotherapy of hepatocellular carcinoma unique challenges and clinical opportunities © 2012 landes bioscience; November. 2015.
[22]
Bishayee, A. The role of inflammation in liver cancer, 2014. In: Inflammation and cancer; 401-435. Springer, Basel.
[23]
Unsal, V.; Belge-Kurutaş, E. Experimental hepatic carcinogenesis: oxidative stress and natural antioxidants. Open Access Maced. J. Med. Sci., 2017, 5(5), 686-691.
[http://dx.doi.org/10.3889/oamjms.2017.101] [PMID: 28932315]
[24]
Niu, Z.S.; Niu, X.J.; Wang, W.H. Genetic alterations in hepatocellular carcinoma: An update. World J. Gastroenterol., 2016, 22(41), 9069-9095.
[http://dx.doi.org/10.3748/wjg.v22.i41.9069] [PMID: 27895396]
[25]
Han, Q.; Zhao, H.; Jiang, Y.; Yin, C.; Zhang, J. HCC-derived exosomes : Critical player and target 2019, 2(Figure 1), 1-11.
[26]
Tian, Z.; Hou, X.; Liu, W.; Han, Z.; Wei, L. Macrophages and hepatocellular carcinoma. Cell Biosci., 2019, 9, 79.
[http://dx.doi.org/10.1186/s13578-019-0342-7] [PMID: 31572568]
[27]
Lee, S.; Loecher, M.; Iyer, R. Immunomodulation in hepatocellular cancer. J. Gastrointest. Oncol., 2018, 9(1), 208-219.
[http://dx.doi.org/10.21037/jgo.2017.06.08] [PMID: 29564186]
[28]
Fang, L.; Choudhary, S.; Zhao, Y.; Edeh, C. B.; Yang, C.; Boldogh, I.; Brasier, A. R.; Ser, T. R. ATM regulates NF- Bdependent immediate-early genes via RelA Ser 276 phosphorylation coupled to CDK9 promoter recruitment. 2014, 42(13), 8416-8432.
[29]
Weiss, T. S.; Rotheneder, H.; Haider, C.; Grubinger, M.; Rezní, E. Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance. 2013, 1947-1958.
[30]
Ham, Y-M.; Choi, K.J.; Song, S.Y.; Jin, Y.H.; Chun, M.W.; Lee, S.K. Xylocydine, a novel inhibitor of cyclin-dependent kinases, prevents the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic cell death of SK-HEP-1 cells. J. Pharmacol. Exp. Ther., 2004, 308(3), 814-819.
[http://dx.doi.org/10.1124/jpet.103.059568] [PMID: 14617691]
[31]
Cho, S.J.; Lee, S.S.; Kim, Y.J.; Park, B.D.; Choi, J.S.; Liu, L.; Ham, Y.M.; Moon Kim, B.; Lee, S.K. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo. Cancer Lett., 2010, 287(2), 196-206.
[http://dx.doi.org/10.1016/j.canlet.2009.06.011] [PMID: 19616371]
[32]
Simone, C.; Bagella, L.; Bellan, C.; Giordano, A. Physical interaction between PRb and Cdk9 / CyclinT2 complex 2002, 4158-4165.
[33]
Wang, B.; Wu, J.; Wu, Y.; Chen, C.; Zou, F.; Wang, A.; Wu, H.; Hu, Z.; Jiang, Z.; Liu, Q.; Wang, W.; Zhang, Y.; Liu, F.; Zhao, M.; Hu, J.; Huang, T.; Ge, J.; Wang, L.; Ren, T.; Wang, Y.; Liu, J.; Liu, Q. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. Eur. J. Med. Chem., 2018, 158, 896-916.
[http://dx.doi.org/10.1016/j.ejmech.2018.09.025] [PMID: 30253346]
[34]
Lin, C.P.; Liu, C.R.; Lee, C.N.; Chan, T.S.; Liu, H.E. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J. Hepatol., 2010, 2(1), 16-20.
[http://dx.doi.org/10.4254/wjh.v2.i1.16] [PMID: 21160952]
[35]
Cho, S.J.; Kim, Y.J.; Surh, Y.J.; Kim, B.M.; Lee, S.K. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J. Biol. Chem., 2011, 286(22), 19662-19671.
[http://dx.doi.org/10.1074/jbc.M110.209551] [PMID: 21478145]
[36]
Lohitesh, K.; Chowdhury, R.; Mukherjee, S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: An insight. Cancer Cell Int., 2018, 18, 44.
[http://dx.doi.org/10.1186/s12935-018-0538-7] [PMID: 29568237]
[37]
Kim, N. G.; Nguyen, P. P.; Dang, H.; Kumari, R.; Garcia, G. temporal trends in disease presentation and survival of patients with hepatocellular carcinoma : A real-world experience from 1998 to 2015 2018, 1-11.
[38]
Shah, C.; Mramba, L.K.; Bishnoi, R.; Bejjanki, H.; Chhatrala, H.S.; Chandana, S.R. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. J. Gastrointest. Oncol., 2017, 8(5), 789-798.
[http://dx.doi.org/10.21037/jgo.2017.06.16] [PMID: 29184682]
[39]
Vogel, A.; Cervantes, A.; Chau, I.; Daniele, B.; Llovet, J.; Meyer, T.; Nault, J.C.; Neumann, U.; Ricke, J.; Sangro, B.; Schirmacher, P.; Verslype, C.; Zech, C.J.; Arnold, D.; Martinelli, E. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2018, 29(Suppl. 4), iv238-iv255.
[http://dx.doi.org/10.1093/annonc/mdy308] [PMID: 30285213]
[40]
Pang, C.; Huang, G.; Luo, K.; Dong, Y.; He, F.; Du, G.; Xiao, M.; Cai, W. miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. Cancer Med., 2017, 6(10), 2398-2409.
[http://dx.doi.org/10.1002/cam4.1188] [PMID: 28940993]
[41]
Yang, N.; Wang, L.; Liu, J.U.N.; Liu, L.I.; Huang, J.; Chen, X.; Luo, Z. MicroRNA-206 regulates the epithelial-mesenchymal transition and inhibits the invasion and metastasis of prostate cancer cells by targeting Annexin A2. Oncol. Lett., 2018, 15(6), 8295-8302.
[42]
Keklikoglou, I.; Hosaka, K.; Bender, C.; Bott, A.; Koerner, C.; Mitra, D.; Will, R.; Woerner, A.; Muenstermann, E.; Wilhelm, H. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene, 2015, 4867-4878.
[43]
Ding, W. MiR-206 suppresses the progression of coronary artery disease by modulating vascular endothelial growth factor (VEGF); Expression, 2016, pp. 5011-5020.
[44]
Liu, H.; Tuckett, A.Z.; Fennell, M.; Garippa, R.; Zakrzewski, J.L. Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation. Invest. New Drugs, 2017, 36(4), 590-600.
[45]
Reilly, E.O.; Dhami, S.P.S.; Baev, D.V.; Ortutay, C.; Halpin-, A.; Morrell, R.; Santocanale, C.; Samali, A.; Quinn, J.; Dwyer, M.E.O. Repression of Mcl-1 Expression by the CDC7 / CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML. Sci. Rep., 8(1), 1-15.
[46]
Jitka, Š.; Martina, Č.; Urbánek, L.; Kry, V.; Hofman, J.; Strnad, M. LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat. J. Chromatog. B., 2018, 1089, 24-32.
[47]
Allegri, L.; Baldan, F.; Mio, C.; Puppin, C.; Russo, D.; Kryštof, V.; Damante, G. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells. Oncol. Rep., 2016, 35(4), 2413-2418.
[http://dx.doi.org/10.3892/or.2016.4614]
[48]
Hyun, S.; Jang, Y. p53 activates G1 checkpoint following DNA damage by doxorubicin during transient mitotic arrest. Oncotarget, 2014, 6(7), 4804.
[49]
Choi, B.Y.; Lee, C.H. Cell cycle arrest and cytochrome c-mediated apoptotic induction by MCS-5A is associated with up-regulation of p16(INK4a) in HL-60 cells. Bioorg. Med. Chem. Lett., 2010, 20(13), 3880-3884.
[http://dx.doi.org/10.1016/j.bmcl.2010.05.037] [PMID: 20627562]
[50]
Kim, B.M.; Jung, S.K.; Lee, S.; Yeol, S. Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL- induced apoptosis via calpain-mediated bax cleavage. Int. J. Biochem. Cell Biol., 2016, 4804
[http://dx.doi.org/10.1016/j.biocel.2016.12.001] [PMID: 27923747]
[51]
Cicenas, J.; Kalyan, K.; Sorokinas, A.; Stankunas, E.; Levy, J.; Stankevicius, V.; Kaupinis, A.; Valius, M. Roscovitine in cancer and other diseases. Ann. Transl. Med., 2015, 3(10), 1-12.
[http://dx.doi.org/10.2210/pdb2a4l/pdb]
[52]
Bettayeb, K.; Baunbæk, D.; Delehouze, C.; Loaëc, N.; Hole, A.J.; Baumli, S.; Endicott, J.A.; Douc-Rasy, S.; Bénard, J.; Oumata, N. CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer, 2010, 1(4), 369-380.
[http://dx.doi.org/10.1177/1947601910369817]
[53]
Yeo, W.; Mok, T.S.; Zee, B.; Leung, T.W.T.; Lai, P.B.S.; Lau, W.Y.; Koh, J.; Mo, F.K.F.; Yu, S.C.H.; Chan, A.T.; Hui, P.; Ma, B.; Lam, K.C.; Ho, W.M.; Wong, H.T.; Tang, A.; Johnson, P.J. A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst., 2005, 97(20), 1532-1538.
[http://dx.doi.org/10.1093/jnci/dji315] [PMID: 16234567]
[54]
Gish, R.G.; Porta, C.; Lazar, L.; Ruff, P.; Feld, R.; Croitoru, A.; Feun, L.; Jeziorski, K.; Leighton, J.; Gallo, J.; Kennealey, G.T. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol., 2007, 25(21), 3069-3075.
[http://dx.doi.org/10.1200/JCO.2006.08.4046] [PMID: 17634485]
[55]
Of, O. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol., 31(28), 3501-3508.
[56]
Johnson, P.; Knox, J. J.; Davidenko, I.; Lacava, J.; Leung, T. Vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma. 2015, 304(19)
[57]
Estfan, B.; Byrne, M.; Kim, R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am. J. Clin. Oncol., 2013, 36(4), 319-324.
[http://dx.doi.org/10.1097/COC.0b013e3182468039] [PMID: 22547010]
[58]
Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W.Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol., 2009, 10(1), 25-34.
[http://dx.doi.org/10.1016/S1470-2045(08)70285-7] [PMID: 19095497]
[59]
Personeni, N.; Pressiani, T.; Rimassa, L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma : Evidence to date; J. Hepatocel. Carcinoma, 2019, pp. 31-39.
[60]
Llovet, J.M. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. J. Hepato. cell. Carcinoma, 2002, 6(31), 429-442.
[61]
Llovet, J.M.; Real, M.I.; Montaña, X.; Planas, R.; Coll, S.; Aponte, J.; Ayuso, C. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. The Lancet, 2002, 359(9319), 1734-1739.
[http://dx.doi.org/10.1016/S0140-6736(02)08649-X]
[62]
Lo, C.M.; Ngan, H.; Tso, W.K.; Liu, C.L.; Lam, C.M.; Poon, R.T.P.; Fan, S.T.; Wong, J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002, 35(5), 1164-1171.
[http://dx.doi.org/10.1053/jhep.2002.33156] [PMID: 11981766]
[63]
Elshaarawy, O.; Gomaa, A.; Omar, H.; Rewisha, E.; Waked, I. Intermediate stage hepatocellular carcinoma: A summary review. J. Hepatocell. Carcinoma, 2019, 6, 105-117.
[http://dx.doi.org/10.2147/JHC.S168682] [PMID: 31372364]
[64]
Raoul, J.L.; Forner, A.; Bolondi, L.; Cheung, T.T.; Kloeckner, R.; de Baere, T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat. Rev., 2019, 72(72), 28-36.
[http://dx.doi.org/10.1016/j.ctrv.2018.11.002] [PMID: 30447470]
[65]
Kudo, M.; Han, G.; Finn, R.S.; Poon, R.T.P.; Blanc, J.; Yan, L.; Yang, J.; Lu, L.; Tak, W.; Yu, X. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology, 60(5), 1697-1707.
[66]
Meyer, T.; Fox, R.; Ma, Y. T.; Ross, P. J.; James, M. W.; Sturgess, R.; Stubbs, C.; Stocken, D. D.; Wall, L.; Watkinson, A. Articles sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma ( TACE 2 ): A randomised placebo-controlled , double-blind , phase 3 trial. Lancet, 2017, 1253(Tace 2), 1-11.
[67]
Kudo, M.; Imanaka, K.; Chida, N.; Nakachi, K.; Tak, W.Y.; Takayama, T.; Yoon, J.H.; Hori, T.; Kumada, H.; Hayashi, N.; Kaneko, S.; Tsubouchi, H.; Suh, D.J.; Furuse, J.; Okusaka, T.; Tanaka, K.; Matsui, O.; Wada, M.; Yamaguchi, I.; Ohya, T.; Meinhardt, G.; Okita, K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer, 2011, 47(14), 2117-2127.
[http://dx.doi.org/10.1016/j.ejca.2011.05.007] [PMID: 21664811]
[68]
Hsu, C.; Lin, L.; Cheng, Y.; Feng, Z.; Shao, Y. Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression. Clin. Cancer Res., 2016, 2555-2565.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0499]
[69]
Outcomes, M.; Registration, T. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs. sorafenib alone for hepatocellular carcinoma with portal vein invasion a randomized clinical trial. JAMA Oncol., 2019, 5(7), 953-960.
[70]
Bazarbachi, A. Inhibition for ATL therapy traffic lights for ruxolitinib. ASH Clin. News, 2017, 130(9), 2016-2018.
[http://dx.doi.org/10.1182/blood-2017-07-793356]

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy